Oviedo-based startup Pragmatech, which develops AI tools for clinical decision-making in healthcare, has secured €650,000 in funding, led by First Drop VC, which invested €300,000.
- Founded in 2021 by Javier Fernández and Pablo Valledor, Pragmatech develops artificial intelligence solutions for the healthcare sector, with a focus on clinical microbiology and infectious diseases. The company creates AI-driven software and analytical tools designed to support clinical decision-making, disease diagnosis, treatment optimization, and healthcare operations.
- Its products rely on data engineering, predictive machine learning models, natural language processing, and advanced optimization techniques, integrating clinical and biological knowledge with analytical data.
- Pragmatech’s flagship product, iAST®, is an AI-powered antibiotic prescribing software that analyzes patient and clinical data to recommend safer and more effective treatment options, aiming to reduce prescribing errors and combat antibiotic resistance.
- The company also provides end-to-end machine learning operations, from model development to deployment and maintenance, ensuring accuracy and compliance with healthcare standards such as ISO13485 and ISO14791.
Details of the deal
- The funding round was led by Valencia-based venture capital firm First Drop VC, which invested €300,000, and included participation from Asturias-based Urriellu Ventures with €175,000, continued support from existing investors, a €180,000 loan from ENISA, and the conversion of €162,500 in previous convertible notes into equity.
- The startup will use the new funding to accelerate the commercial rollout of its AI-powered iAST® software, refine the technology, and expand its presence in the healthcare AI market.
- The investment will help hospitals and healthcare professionals implement the tool effectively, promote safer antibiotic prescribing, and strengthen Pragmatech’s position as a leader in digital healthcare solutions.
“This funding not only enables us to roll out iAST® at a commercial level, but also provides us with the resources necessary to continue refining our products and to ensure that artificial intelligence supports clinical decision-making in a safe and effective manner," explains Pablo Valledor, co-CEO and CTO of Pragmatech.
